Cancer News and Research

Latest Cancer News and Research

African-American women with advanced breast cancer have poorer survival rates

African-American women have poorer survival rates than their white and Hispanic counterparts regardless of whether they receive radiation therapy following lumpectomy or mastectomy, UC Davis researchers have found.

7 Apr 2010

Nationwide Phase III clinical trial of OncoVEX for advanced melanoma

Rush University Medical Center is leading a nationwide Phase III clinical trial to determine whether a promising vaccine for advanced melanoma can effectively treat the deadly skin cancer.

7 Apr 2010

OXiGENE regains compliance for continued listing on NASDAQ Global Market

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Howson to the Company's audit committee, as detailed in the Company's Form 8-K filed on April 5, 2010, NASDAQ staff has determined that the Company complies with Listing Rule 5605(c)(2)

7 Apr 2010

BD Diagnostics adds Innova Preanalytical Automated Microbiology Specimen Processor to product portfolio

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today the expansion of its product portfolio with the addition of the BD Innova™ Preanalytical Automated Microbiology Specimen Processor, which is designed to help increase laboratory efficiency and automate the modern microbiology laboratory.

From BD (Becton, Dickinson and Company) 7 Apr 2010

Soccer for Health

Led by Professors Peter Krustrup and Jens Bangsbo from the Department of Exercise and Sports Sciences, University of Copenhagen, the 3-year project covered several intervention studies involving both men, women and children, who were divided into soccer, running and control groups.

7 Apr 2010

Avastin approval to drive ovarian cancer drug market to $1.5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ovarian cancer drug market -- driven by the approval and rapid uptake of Roche/Genentech/Chugai's Avastin -- will more than triple from $449 million in 2008 to just under $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

7 Apr 2010

Reverse Medical signs strategic partnership agreement with Getz Bros.

Reverse Medical Corporation today announced it has entered into a strategic partnership agreement with Getz Bros. & Company, Inc., for distribution of Reverse Medical devices throughout the Pacific Rim. Getz is an international marketing and medical distribution services company with over 50 offices in 24 countries around the world, and has an excellent reputation for global distribution.

7 Apr 2010

Financial stake in surgery centers motivates doctors to operate more often

When doctors become invested in an outpatient surgery center, they perform on average twice as many surgeries as doctors with no such financial stake, according to a new study from the University of Michigan Health System.

7 Apr 2010

New extra potent sunscreens in the pipeline

Sunscreens are touted to protect your skin from the harmful ultraviolet rays of the sun. However scientists are now studying whether a good sunscreen protects your skin even after your skin is no longer exposed to the sun? This study is undertaken because of the alarming rise in malignant melanoma, a form of skin cancer that is linked to the sun’s UV rays. Malignant melanoma is the most common cancer in Australia and Queensland tops all other places in the world when it comes to incidence of this skin cancer.

7 Apr 2010

Blocking POLQ gene activity can increase ability of radiotherapy to destroy tumours

Cancer Research UK scientists have identified a gene that once blocked could increase the effectiveness of radiotherapy on tumours, according to research published in Cancer Research today (Thursday).

7 Apr 2010

MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL), in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. The trial, led by Shaji Kumar, MD, of Mayo Clinic, is open for enrollment at Mayo Clinic (Rochester, Minn.), City of Hope Cancer Center (Duarte, Calif.) and the University of Chicago (Chicago, Ill).

7 Apr 2010

Five helpings of fruits and vegetables a day may not cut cancer risk that much

Despite eating your five helpings of fruits and vegetables a day you may not be cutting your risk of cancer as suggested by a World Health organization study in 1997. The latest study based on healthy eating habits conducted by Mount Sinai School of Medicine in New York was published in the Journal of National Cancer Institute. The study was led by Paolo Boffetta and covered almost 500,000 Europeans.

7 Apr 2010

20 regional cancer care units to get $560 million for upgrades

There is good news for millions of cancer patients across Australia. Prime Minister Rudd has announced a contribution of $560 million with the intention of upgrading and opening new cancer centers in regional and rural communities all over Australia.

7 Apr 2010

IPS examines malnutrition, obesity in Latin America

Inter Press Service examines malnutrition and factors contributing to the rising rates of "obesity and obesity-related illness - such as type II diabetes, high blood pressure, heart disease, some forms of cancer and osteoporosis - in Latin America, and especially among the poorest sectors of the population."

7 Apr 2010

Research shows direct link between dental health and general health

Research has shown a direct link between the health of our mouths and our general health. Periodontal (gum) disease may increase adult risk of diseases such as heart, stroke, diabetes and respiratory diseases. Tooth and gum disease and is one of the most common dental problems of older adults.

7 Apr 2010

CancerGuide Diagnostics, Duke University form cancer research collaboration and licensing agreement

CancerGuide Diagnostics™, Inc. today announced that it has entered into a research collaboration and licensing agreement with Duke University to discover and develop tests to support individualized cancer treatment decisions.

7 Apr 2010

Newer treatments, closer monitoring of childhood cancer may improve longevity

Although more children today are surviving cancer than ever before, young patients successfully treated in the 1970s and 80s may live a decade less, on average, than the general population, according to a study from Dana-Farber Cancer Institute and the Harvard School of Public Health.

7 Apr 2010

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Genta Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's request for "Fast Track" designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

7 Apr 2010

IGRAs effective for detecting confirmed active TB disease: CHEST

New data from a meta-analysis of existing literature published today in CHEST, the official journal of the American College of Chest Physicians, demonstrate that Interferon Gamma Release Assays are superior to the previous standard in diagnostics, the 100+-year-old tuberculin skin test, for detecting confirmed active Tuberculosis disease.

7 Apr 2010

Accumetrics completes enrollment phase of GRAVITAS clinical trial

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.

7 Apr 2010